Aliki Taylor is Executive Director of Epidemiology at Gilead Sciences, where she leads Real‑World Evidence in Oncology. In this role, Aliki oversees the strategy and delivery of real‑world studies across the oncology portfolio, spanning early development through post‑launch. Aliki has over 15 years' experience in the pharmaceutical industry, holding senior epidemiology leadership roles in oncology at AstraZeneca, Takeda and Amgen. Prior to industry, Aliki worked in academia and completed a Fellowship and PhD in Cancer Epidemiology. Aliki trained in medicine at UCL in London and worked in the NHS, completing specialist training in Public Health Medicine.
A discussion on how leadership in pharmacovigilance is evolving in response to increasing data, regulatory expectations, and technological change.
Michael Ramcharan
Managing Director at Reumat Consulting
Puja Myles
Director, Clinical Practice Research Datalink at Medicines and Healthcare products Regulatory Agency
Joanne Rogerson
Director of Operations at Resolver
Sandra Reda
Senior Pharmacovigilance Specialist at Newbridge Pharmaceuticals
Jean-Marc C. Haeusler
Global Head International Patient Safety at Roche
Aliki Taylor
Executive Director, RWE TA Head - Oncology at Gilead Sciences
Aliki Taylor
Executive Director, RWE TA Head - Oncology at Gilead Sciences
For general conference and registration enquires please contact the below email id or via call
Login 
Wednesday - June 17, 2026
11:30
AM -
12:00
PM 
30
Minutes
info@corvusglobalevents.com
+44
(0)
207
096 0786
